Zydus Lifesciences (ZYDUSLIFE) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE010B01027
Key metrics
- Market Cap
- ₹1.12 L Cr
- P/E Ratio
- 25.05
- EPS
- 44.87
- Book Value
- 293.99
- P/B Ratio
- 3.82
- ROE
- 17.04%
- ROCE
- 13.75%
- Debt / Equity
- 0.42
- Net Margin
- 18.86%
- Revenue Growth
- 18.37%
- Profit Growth
- 11.37%
- Dividend Yield
- 0.09%
- 52W High
- ₹1,232.10
- 52W Low
- ₹835.50
- Market Cap Band
- large cap
- Face Value
- 1
Ratios computed from the annual results period ending 2026-03-31.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
- Headquarters
- Ahmedabad, India
- Employees
- 29,980
- Promoter Holding
- 75.18%
Zydus Lifesciences and the Drug Manufacturers - Specialty & Generic industry
Zydus Lifesciences is one of 153 listed companies in the Drug Manufacturers - Specialty & Generic industry. At a P/E of 25.1, it trades below the industry median of 30.6.
All Drug Manufacturers - Specialty & Generic stocks →Healthcare sector stocks →
Related companies
- Sun Pharmaceutical IndustriesSUNPHARMA · ₹1,743.00₹4.22 L Cr
- Divi's LaboratoriesDIVISLAB · ₹9,087.00₹2.43 L Cr
- Torrent PharmaceuticalsTORNTPHARM · ₹4,558.70₹1.74 L Cr
- Laurus LabsLAURUSLABS · ₹2,069.00₹1.11 L Cr
- CiplaCIPLA · ₹1,324.10₹1.07 L Cr
- Dr. Reddy's LaboratoriesDRREDDY · ₹1,242.50₹1.03 L Cr
- Aurobindo PharmaAUROPHARMA · ₹1,621.40₹95,910 Cr
- Mankind PharmaMANKIND · ₹2,253.20₹93,988 Cr
Zydus Lifesciences: key questions
What does Zydus Lifesciences do?
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies.
What is the share price of Zydus Lifesciences?
Zydus Lifesciences (ZYDUSLIFE) last traded at ₹1,113.90 on the NSE, down 0.8% on the day. Over the past 52 weeks it has traded between ₹835.50 and ₹1,232.10. The current price is 9.6% below its 52-week high.
What is the market cap of Zydus Lifesciences?
Zydus Lifesciences has a market capitalisation of ₹1.12 L Cr, which makes it a large-cap company. It is the 4th largest of 153 listed companies in the Drug Manufacturers - Specialty & Generic industry by market capitalisation.
What is the P/E ratio of Zydus Lifesciences?
Zydus Lifesciences trades at a price-to-earnings (P/E) ratio of 25.1. The median P/E across profitable companies in the Drug Manufacturers - Specialty & Generic industry is 30.6.
What are Zydus Lifesciences's ROE and ROCE?
For the financial year ended March 2026, Zydus Lifesciences reported a return on equity (ROE) of 17.0%, a return on capital employed (ROCE) of 13.8% and a net profit margin of 18.9%.
How fast is Zydus Lifesciences growing?
In the financial year ended March 2026, Zydus Lifesciences's revenue grew 18.4% and net profit grew 11.4% compared with the previous year.
Does Zydus Lifesciences have debt?
Zydus Lifesciences has a debt-to-equity ratio of 0.42, meaning borrowings are about 42% of shareholders' equity.
Does Zydus Lifesciences pay a dividend?
Zydus Lifesciences has a dividend yield of 0.09% at the current share price.
What is the promoter holding in Zydus Lifesciences?
Promoters hold 75.2% of Zydus Lifesciences. Institutional investors hold 15.5%.
Which companies are similar to Zydus Lifesciences?
Listed companies close to Zydus Lifesciences in size within the Drug Manufacturers - Specialty & Generic industry include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Laurus Labs, Cipla and Dr. Reddy's Laboratories.
Figures are for information only and are not investment advice.
The full Zydus Lifesciences analysis
Create a free account to open the complete ZYDUSLIFE deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.